Citadel Advisors
CTXR icon

Citadel Advisors’s Citius Pharmaceuticals CTXR Stock Holding History

Citadel Advisors’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,900
Closed -$13.5K – 12844
2025
Q3 		$13.5K Sell
10,900
-14,800
-58% -$20.6K ﹤0.01% 12546
2025
Q2 		$40.9K Buy
25,700
+15,900
+162% +$14.6K ﹤0.01% 11870
2025
Q1 		$14.6K Sell
9,800
-15,840
-62% -$37.9K ﹤0.01% 13353
2024
Q4 		$103K Buy
25,640
+24,356
+1,897% +$164K ﹤0.01% 11445
2024
Q3 		$16.1K Buy
+1,284
New +$21.6K ﹤0.01% 12944
2024
Q1 		– Sell
-716
Closed -$13.5K – 14672
2023
Q4 		$13.5K Sell
716
-4
-0.6% -$76 ﹤0.01% 12924
2023
Q3 		$12.3K Sell
720
-16
-2% -$380 ﹤0.01% 12972
2023
Q2 		$22.1K Sell
736
-296
-29% -$9.74K ﹤0.01% 12640
2023
Q1 		$30.2K Sell
1,032
-32
-3% -$922 ﹤0.01% 12735
2022
Q4 		$21K Buy
1,064
+28
+3% +$764 ﹤0.01% 13111
2022
Q3 		$31K Buy
1,036
+24
+2% +$660 ﹤0.01% 11890
2022
Q2 		$23K Sell
1,012
-16
-2% -$439 ﹤0.01% 12346
2022
Q1 		$46K Sell
1,028
-588
-36% -$23.2K ﹤0.01% 12843
2021
Q4 		$62K Sell
1,616
-748
-32% -$33.9K ﹤0.01% 13118
2021
Q3 		$120K Buy
+2,364
New +$119K ﹤0.01% 12644

Other funds holding CTXR

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MFS
Miller Financial Services Marshall, Michigan $124M AUM 17.62% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
AAG
Asset Advisory Group Kinnelon, New Jersey $229M AUM
BW
BostonPremier Wealth Hanover, Massachusetts $235M AUM 31.01% 1-Year Est. Return

Citadel Advisors's CTXR Position: Q2 2026 in Review

Citadel Advisors opened a new position in Citius Pharmaceuticals (CTXR) in Q2 2026: 124,910 shares worth $75.5K. The stake represents ﹤0.01% of the portfolio and ranks #12876 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in CTXR as recently as Q4 2024.

Citadel Advisors first reported a position in CTXR in Q1 2019 and has held it in 18 quarters since. The position peaked at $728K in Q2 2021. 43 funds tracked by Wall St. Rank hold CTXR as of Q2 2026.

  • Citadel Advisors held 124,910 shares of Citius Pharmaceuticals worth $75.5K as of Q2 2026.
  • Citius Pharmaceuticals was a new Citadel Advisors position in Q2 2026.
  • Citius Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12876 holding.
  • Citadel Advisors first reported a position in Citius Pharmaceuticals in Q1 2019 and has held it in 18 quarters since.
  • Citadel Advisors's Citius Pharmaceuticals position peaked at $728K in Q2 2021.
  • 43 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.